Q32 Bio (QTTB) Total Current Liabilities (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Total Current Liabilities of $10.7 million for Q1 2026, down 26.82% year-over-year from $14.6 million in Q1 2025, and down 5.97% quarter-over-quarter from $11.3 million in Q4 2025.
Q32 Bio (QTTB) Total Current Liabilities (2017 - 2026) Analysis & Trends
Q32 Bio's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $10.7 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 26.82% year-over-year to $10.7 million; the TTM figure through Mar 2026 stood at $10.7 million (down 26.82% YoY), while the FY2025 annual figure was $11.3 million, down 31.09% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $10.7 million, down from $11.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $33.0 million in Q1 2024, with the low at $10.7 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $17.2 million (2024), against an average of $18.3 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 78.06% in 2024, then plunged 55.76% in 2025.
- Q32 Bio's Total Current Liabilities stood at $22.6 million in 2022, then plunged by 37.5% to $14.1 million in 2023, then rose by 16.7% to $16.5 million in 2024, then tumbled by 31.09% to $11.3 million in 2025, then slipped by 5.97% to $10.7 million in 2026.
- Business Quant data shows QTTB's Total Current Liabilities at $10.7 million in Q1 2026, $11.3 million in Q4 2025, and $11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.40 Mn |
| Mar 31, 2026 | 10.67 Mn |
| Dec 31, 2025 | 11.35 Mn |
| Sep 30, 2025 | 11.11 Mn |
| Jun 30, 2025 | 11.53 Mn |
| Mar 31, 2025 | 14.58 Mn |
| Dec 31, 2024 | 16.47 Mn |
| Sep 30, 2024 | 14.38 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Mar 31, 2024 | 32.95 Mn |
| Dec 31, 2023 | 14.11 Mn |
| Sep 30, 2023 | 25.29 Mn |
| Jun 30, 2023 | 22.94 Mn |
| Mar 31, 2023 | 18.51 Mn |
| Dec 31, 2022 | 22.58 Mn |
| Sep 30, 2022 | 25.25 Mn |
| Jun 30, 2022 | 20.73 Mn |
| Mar 31, 2022 | 20.80 Mn |
| Dec 31, 2021 | 17.23 Mn |
| Sep 30, 2021 | 18.71 Mn |